Stability Testing for Production Cell Lines: What ICH Q5B Requires

ICH Q5B is one of the foundational guidance documents in biologics CMC, and it governs something that sits at the core of every recombinant protein program: the genetic integrity and stability of your expression construct over the production lifespan of the cell line. Understanding what Q5B requires — and how to plan your stability program to satisfy it efficiently — is essential for any team preparing an IND or BLA for a mammalian cell-derived biologic.

What ICH Q5B Actually Governs

ICH Q5B — "Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products" — establishes the expectations for characterizing the genetic integrity and stability of your expression construct in the production cell line. It applies to recombinant DNA-derived proteins produced in mammalian, microbial, insect, and yeast expression systems, and is referenced in both US and EU regulatory submissions.

The guidance requires characterization of the expression vector, the integrated insert(s), the copy number, the arrangement of the construct, and the stability of all of these features over the production lifespan of the cell line. It is not a standalone document — it is operationally linked to ICH Q5D (cell banking and testing) and ICH Q5A (adventitious agents), and a complete regulatory filing integrates all three.

Q5B compliance is a scientific story about your expression system — not a checkbox. The programs that navigate it most smoothly plan construct documentation and stability studies concurrently with cell banking, not retrospectively.

Stability Studies: Timelines, Passages, and What to Measure

The core stability requirement in Q5B is demonstrating that the production cell line maintains genetic stability and product quality across the full range of passages expected during production use — from the master cell bank (MCB) to end-of-production (EOP). For most fed-batch mammalian cell culture processes, EOP corresponds to approximately 60–70 population doublings from the MCB.

Stability endpoints include:

• Titer and specific productivity
• Intact mass and peptide mapping to confirm protein sequence integrity
• Copy number by ddPCR or qPCR
• Southern blot or NGS-based construct integrity analysis to detect rearrangements
• Product quality attributes: glycan profile, charge variants, aggregation
• RNA-level analysis (RT-PCR) to confirm transcript integrity

Any drift of more than 20–25% in titer or a meaningful shift in glycan distribution between MCB and EOP passages is a finding that requires explanation and may require additional investigation before IND filing.

Documenting the Expression Construct

Beyond stability, Q5B requires comprehensive documentation of the expression construct itself — the plasmid used for transfection, the gene of interest sequence, the promoter and regulatory elements, the selectable marker, and the vector backbone. For integration-based systems (random integration or targeted integration using CRISPR, TALEN, or ZFN), the integration site(s) should be characterized where feasible, using techniques such as ligation-mediated PCR or whole-genome sequencing.

Integration site characterization is not explicitly mandated for all products, but FDA and EMA reviewers increasingly expect it for programs that use site-specific integration as a differentiating element of the expression system. If your cell line development platform relies on targeted integration, budget for integration site characterization early — it takes time and is much harder to execute retrospectively after the MCB is frozen.

Connecting Q5B Data to the Cell Bank Testing Package

ICH Q5B is operationally inseparable from ICH Q5D, which governs cell banking and testing. A complete regulatory filing links Q5B construct characterization data to the Q5D cell bank testing package, which includes MCB and WCB identity, purity (adventitious agents testing per ICH Q5A), and characterization.

The construct integrity and copy number data you generate for Q5B are most usefully generated on material drawn from the MCB, so that the cell bank and the construct characterization are documented at the same defined starting point. EOP stability data, generated by expanding MCB material through the maximum number of production passages, closes the loop by demonstrating that the construct documented at MCB is still intact and stable at EOP.

Q5B compliance is not a checkbox — it is a scientific story about your expression system. The programs that navigate it most smoothly are those that plan the construct documentation and stability studies concurrently with cell banking, not retrospectively. Starting early allows you to identify and address any unexpected findings before they become IND filing delays.